TY - JOUR
T1 - Bacterial Pneumonias in Immunocompromised Patients
AU - Van De Louw, Andry
AU - Mirouse, Adrien
AU - Peyrony, Olivier
AU - Lemiale, Virginie
AU - Azoulay, Elie
N1 - Funding Information:
Dr. Azoulay reports personal fees and non-financial support from Pfizer, personal fees from Alexion, personal fees from MSD, grants and personal fees from Baxter, grants from Ablynx, outside the submitted work. Dr. Peyrony reports personal fees from BMS, outside the submitted work.
Publisher Copyright:
© 2019 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
PY - 2019
Y1 - 2019
N2 - With the overall improvement in survival of cancer patients and the widespread use of novel immunotherapy drugs for malignant as well as nonmalignant diseases, the prevalence of immunosuppression is rising in the population. Immunocompromised patients are particularly exposed to pulmonary infections which remain a leading cause for acute hypoxic respiratory failure and intensive care unit admission. Although fungal or opportunistic infections are always a concern, bacterial pneumonia remains the most common cause of pulmonary infection, is associated with a significant mortality, and has some specificity in this population. Adequate and timely prevention, diagnosis, and management of bacterial pneumonias require knowledge about the complex interplay between host factors (type and severity of immunosuppression) and bacterial pathogenesis, to improve the outcome. We provide an overview of bacterial pneumonias in immunocompromised patients including their epidemiology, risk factors with respect to the pattern of immunosuppression, microbiological characteristics, diagnostic approach, management, and prevention.
AB - With the overall improvement in survival of cancer patients and the widespread use of novel immunotherapy drugs for malignant as well as nonmalignant diseases, the prevalence of immunosuppression is rising in the population. Immunocompromised patients are particularly exposed to pulmonary infections which remain a leading cause for acute hypoxic respiratory failure and intensive care unit admission. Although fungal or opportunistic infections are always a concern, bacterial pneumonia remains the most common cause of pulmonary infection, is associated with a significant mortality, and has some specificity in this population. Adequate and timely prevention, diagnosis, and management of bacterial pneumonias require knowledge about the complex interplay between host factors (type and severity of immunosuppression) and bacterial pathogenesis, to improve the outcome. We provide an overview of bacterial pneumonias in immunocompromised patients including their epidemiology, risk factors with respect to the pattern of immunosuppression, microbiological characteristics, diagnostic approach, management, and prevention.
UR - http://www.scopus.com/inward/record.url?scp=85072925589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072925589&partnerID=8YFLogxK
U2 - 10.1055/s-0039-1696961
DO - 10.1055/s-0039-1696961
M3 - Article
C2 - 31585476
AN - SCOPUS:85072925589
SN - 1069-3424
VL - 40
SP - 498
EP - 507
JO - Seminars in Respiratory and Critical Care Medicine
JF - Seminars in Respiratory and Critical Care Medicine
IS - 4
ER -
